Neuropathy Associated with Systemic Amyloidosis.

  title={Neuropathy Associated with Systemic Amyloidosis.},
  author={Michelle C Kaku and John L Berk},
  journal={Seminars in neurology},
  volume={39 5},
  • M. Kaku, J. Berk
  • Published 1 October 2019
  • Medicine, Biology, Psychology
  • Seminars in neurology
Peripheral neuropathy occurs in the setting of both hereditary and acquired amyloidosis. The most common form of hereditary amyloidosis is caused by 1 of 140 mutations in the transthyretin (TTR) gene, which can lead to neuropathic hereditary transthyretin amyloidosis (hATTR; previously referred to as transthyretin familial amyloid polyneuropathy), whereas acquired immunoglobulin light chain (AL) amyloidosis is the most common acquired form. Patients typically present with a sensorimotor… 

Figures from this paper

Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis
The considerable therapeutic advances have raised additional challenges, including optimisation of diagnostic techniques and management approaches in ATTRv neuropathy, as well as improvement in quality of life and functional outcomes.
Amyloid Proteins and Peripheral Neuropathy
It is concluded that there are many similarities in the molecular and cell biological defects caused by aggregation of the various amyloid proteins in these different diseases and a common pathogenic pathway for “peripheral amyloids neuropathies” is proposed.
Interpreting signals from the peripheral nerve in amyloidosis: a call for action
In this review, the neurological clinical aspects that induce a suspicion of amyloidosis, the possible differential diagnosis and the diagnostic pitfalls are emphasized.
Neuromuscular amyloidosis: Unmasking the master of disguise
The clinical manifestations of neuromuscular amyloidosis are reviewed and a diagnostic approach to this disorder is provided, which involves small myelinated and unmyelinated sensory and autonomic nerve fibers early in the course of the disease, followed by large myelination sensory and motor deficits.
Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays.
Higher rates of polyneuropathy by examination than patient-reported symptoms are found, especially among those with V122I TTR amyloidosis, signalling asymptomatic polyneurpathy.
Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being
The impacts of hATTR amyloidosis were profound for the patients interviewed for this study, and they described a sense of loss as their condition progressed and impacted them physically, emotionally, and socially.
Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis
Peripheral nervous function deteriorates more rapidly in patients with ATTRv-PN than for other peripheral neuropathies, and the development of assessment tools and therapies specifically targeting neuropathic progression in this debilitating disease is guided.
Diagnostic challenges in systemic amyloidosis: a case report with clinical and laboratorial pitfalls
This case report exemplifies clinical and laboratory pitfalls in diagnosing amyloidosis and subtyping amyloids, exposing the patient to potentially harmful procedures.
Paraproteinemias and Peripheral Nerve Disease.


The molecular biology and clinical features of amyloid neuropathy
A study is ongoing to determine whether amyloid deposition can be inhibited by small organic molecules that are hypothesized to affect the fibril‐forming ability of transthyretin.
Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy
The need to look for an alternative diagnosis in CIDP patients who do not respond to treatment and to look carefully for symptoms or signs of autonomic involvement in such patients is emphasized.
TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients
Clinicians should consider screening for TTR mutations in patients presenting with progressive axonal polyneuropathy of undetermined etiology, including apparently sporadic cases with pathological examinations negative for amyloid deposition, to avoid misdiagnosis.
Transthyretin amyloidosis: A new mutation associated with dementia
Members of a kindred affected by a slowly progressive dementia, seizures, ataxia, hemiparesis, and decreased vision without neuropathy have TTR amyloid deposits in the leptomeninges, the brain parenchyma, and the eye.
Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis.
We report a middle-aged woman with a novel transthyretin (TTR) variant, Leu12Pro. She had extensive amyloid deposition in the leptomeninges and liver as well as the involvement of the heart and
Peripheral neuropathy as an early marker of AL amyloidosis.
Peripheral neuropathy is not an uncommon symptom of primary amyloidosis and may mark the onset of the disease process years before infiltration of vital structures of the heart, kidneys or gastrointestinal tract leads to failure and a subsequent downhill course.
Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm
A consolidated review of the ATTR-FAP Val30Met landscape in Japan is presented and findings are summarized from a medical advisory board meeting held in Tokyo on 18th August 2016, at which a Japan-specific ATTR -FAP red-flag symptom cluster and treatment algorithm was developed.
Peripheral neuropathy in wild type transthyretin amyloidosis. (P1.438)
Examination of records of patients diagnosed with wild type TTR amyloidosis found symptoms of peripheral neuropathy are common in patients with ATTRwt and clinical presentation is sometimes masked by the history of spine disease and should be better evaluated.